Showing 1341-1350 of 3103 results for "".
- Evobrutinib Reduces Relapse Rate, Lesion Load, and Neurofilament Light Levelshttps://practicalneurology.com/news/evobrutinib-reduces-relapse-rate-lesion-load-and-neurofilament-light-levels/2469571/Post-hoc analysis of data from a trial (NCT02975349) of evobrutinib (EMD Serono, Rockland, MA) for relapsing forms of multiple sclerosis (MS) showed reduced levels of neurofilament light (NfL), a biomarker of axon degeneration. Partici
- Tolebrutinib Reduces New Lesions in People with Highly Active Multiple Sclerosishttps://practicalneurology.com/news/tolebrutinib-reduces-new-lesions-in-people-with-highly-active-multliple-sclerosis/2469556/A subgroup analysis of participants with highly active multiple sclerosis (MS) in a clinical trial (NCT03889639) of tolebrutinib (Sanofi; Bridgewater, NJ) had reduced disease activity with tolebrutinib vs placebo. After 12 weeks of tre
- Nabiximols for Multiple Sclerosis-Associated Spasticity Phase 3 Studies in US Beginhttps://practicalneurology.com/news/nabiximols-for-multiple-sclerosis-associated-spasticity-phase-3-studies-in-us-begin/2469416/The first phase 3 clinical trial (NCT04203498) studying the cannabis-derived medicine nabiximols (Sativex; GW Pharmaceuticals, Carlsbad, CA) for spasticity in multiple sclerosis (MS) has been initi
- Blood Test May Help Predict Disease Progression in Individuals with Multiple Sclerosishttps://practicalneurology.com/news/blood-test-may-help-predict-disease-progression-in-individuals-with-multiple-sclerosis/2469268/A study published in Neurology shows that a blood test may help predict worsening of multiple sclerosis (MS) likely to occur within the next year. The test can detect a neurofilament light (NfL) cha
- New Drug Application for Ponesimod Was Submitted to FDAhttps://practicalneurology.com/news/new-drug-application-for-ponesimod-was-submitted-to-fda/2469195/A new drug application (NDA) for ponesimod (Janssen Pharmaceutical, Titusville, NJ) for the treatment of adults with relapsing multiple sclerosis (MS), was submitted to the Food and Drug Administration (FDA). At week 108, a statistically significant reduction in annualized relapse rate
- Ponesimod Superior to Teriflunomide for Relapsing Multiple Sclerosis in Phase 3 Trialhttps://practicalneurology.com/news/ponesimod-superior-to-teriflunomide-for-relapsing-multiple-sclerosis-in-phase-3-trial/2469015/In the phase 3 OPTIMUM study (NCT02425644), adults with relapsing multiple sclerosis (MS) treated with ponesimod (Janssen Pharmaceuticals, Titusville, NJ) had a 30.5% reduction in annualized relapse rate (ARR) compared with those treat
- Determining Optimal Treatment Strategies for Multiple Sclerosishttps://practicalneurology.com/news/determining-optimal-treatment-strategies-for-multiple-sclerosis/2468988/A review published in Lancet Neurology makes the case that well-powered randomized clinical trials to compare treatment strategies for multiple sclerosis (MS) are necessary and possible. Authore
- Patient's Risk Tolerance for Disease Modifying Treatments for Multiple Sclerosishttps://practicalneurology.com/news/patients-risk-tolerance-for-disease-modifying-treatments-for-multiple/2468799/In a study published in Neurology, researchers at the Cleveland Clinic evaluated patients’ tolerance for potential risks of multiple sclerosis (MS) medications. Studies show that 40% or more of
- Multiple Sclerosis Prevalence May Be Twice As High as Previously Thoughthttps://practicalneurology.com/news/multiple-sclerosis-prevalence-may-be-twice-as-high-as-previously-thought/2468830/A study published in the journal Neurology suggests prevalence of multiple sclerosis (MS) in the US is 913,925—more than twice the previous estimate of 400,000 people in
- 2024 Lifetime Achievement Award in Alzheimer’s Disease Therapeutic Research Presented to Lars Lannfelt, MD, PhDhttps://practicalneurology.com/news/2024-lifetime-achievement-award-in-alzheimers-disease-therapeutic-research-presented-to-lars-lannfelt-md-phd/2470618/Lars Lannfelt, MD, PhD has been recognized as the recipient of the 2024 Lifetime Achievement Award in Alzheimer’s Disease Therapeutic Research at the 17th annual Clinical Trials on Alzheimer’s Disease (CTAD) conference. Dr. Lannfelt was selected based on his pioneering work in Alzheim